StockData
Johnson & Johnson logo

Johnson & Johnson

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q3 FY2026, quarter ended Sep 27, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3076% above fair value
$266.17−4.39 (-1.62%)

Close on Nov 3, 2026Market cap $641.44BP/E 40.4Yield 1.93%

Johnson & Johnson Other Pulmonary Hypertension medicines by Quarter

Other Pulmonary Hypertension medicines — Worldwide sales ($M) ($M)

QuarterlyAnnual

Johnson & Johnson Other Pulmonary Hypertension medicines: $42M in Q3 2026, down 20.8% from a year earlier.

Latest, Q3 2026
42
Period ended Sep 30, 2026
Change on a year earlier
-20.8%
53 in Q3 2025
History
39 quarters
Since Q1 2017
Sources
31
Documents cited below

Where the Q3 2026 figure comes from

Source: Form 10-Q (filed 2026-10-21) ↗

Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther Pulmonary Hypertension medicines — Worldwide sales ($M) ($M)Year on yearSource
Q3 2026Sep 30, 202642-20.8%Form 10-Q (filed 2026-10-21) ↗
Q2 2026Jun 28, 202647-14.5%Form 10-Q (filed 2026-07-23) ↗
Q1 2026Mar 29, 202646-11.5%Form 10-Q (filed 2026-04-22) ↗
Q4 2025Dec 28, 202549-14.0%Form 10-K (filed 2026-02-11) ↗
Q3 2025Sep 28, 202553-11.7%Form 10-Q (filed 2026-10-21) ↗
Q2 2025Jun 29, 202555-17.9%Form 10-Q (filed 2026-07-23) ↗
Q1 2025Mar 30, 202552-7.1%Form 10-Q (filed 2026-04-22) ↗
Q4 2024Dec 29, 202457-6.6%Form 10-K (filed 2026-02-11) ↗
Q3 2024Sep 29, 202460-4.8%Form 10-Q (filed 2025-10-22) ↗
Q2 2024Jun 30, 202467+1.5%Form 10-Q (filed 2025-07-24) ↗
Q1 2024Mar 31, 202456-20.0%Form 10-Q (filed 2025-04-23) ↗
Q4 2023Dec 31, 202361-17.6%Form 10-K (filed 2026-02-11) ↗
Q3 2023Oct 1, 202363-19.2%Form 10-Q (filed 2024-10-23) ↗
Q2 2023Jul 2, 202366-15.4%Form 10-Q (filed 2024-07-25) ↗
Q1 2023Apr 2, 202370-15.7%Form 10-Q (filed 2024-05-01) ↗
Q4 2022Jan 1, 202374-21.3%Form 10-K (filed 2025-02-13) ↗

Breakdown

What makes up other Pulmonary Hypertension medicines

Cite this data

StockData. (2026). Johnson & Johnson Other Pulmonary Hypertension medicines ($M), quarterly Q1 2017–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-other-ph

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.

See a number that looks wrong?